Canada markets open in 1 hour 21 minutes

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
6.05+0.26 (+4.49%)
At close: 3:56PM EDT
Full screen
Previous Close5.79
Open0.00
Bid6.02 x N/A
Ask6.05 x N/A
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume22,872
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
    Newsfile

    Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company") is pleased to announce, after very encouraging preliminary in vivo results, the establishment of a collaboration with the HUS Comprehensive Cancer Center at Helsinki, Finland for the optimization of Defence's Accum-T-DM1 ADC Therapeutic. This Cancer Center is Finland's largest and most versatile cancer treatment center, their expertise is internationally highly valued

  • RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
    Newsfile

    RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

    Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical stage biotechnology company pioneering ADCs and therapeutics targeting cancer and infectious diseases. Defence is developing these transformative medicines for catastrophic illnesses and is please to provide an update on its COVID-19 vaccine program with its first lead candidate AccuVAC-PT001 (study initiated in Q4 of 2020).Defence's ACCUMTM platform opens a new biotherapeutic modality by ensuring ...

  • Newsfile

    Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

    Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical stage biotechnology company pioneering ADCs and therapeutics targeting cancer and infectious diseases. Defence is developing these transformative medicines for catastrophic illnesses and is please to provide an update on its COVID-19 vaccine program with its first lead candidate AccuVAC-PT001 (study initiated in Q4 of 2020). Defence's ACCUMTM platform opens a new biotherapeutic modality by ...